<DOC>
	<DOCNO>NCT00235560</DOCNO>
	<brief_summary>These study design evaluate tolerability efficacy sirolimus ( rapamycin ) combination low-dose aracytin elderly AML .</brief_summary>
	<brief_title>Rapamycin Combination With Low-Dose Aracytin Elderly Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description>Evaluate tolerability efficacy sirolimus ( rapamycin ) combination low-dose aracytin</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age &gt; 60 . Informed consent de novo secondary LAM ( CML exclude ) elligible intensive chemotherapy . Previously untreated Renal impairment ( serum creatinin &gt; 2N ) Hepatic impairment ( TGO ou TGP &gt; 5N ) , une cholestase ( Phosphatases Alcalines gammaGT &gt; 5N ) , bilirubin &gt; 3N Blast crisis CML Acute Promyelocytic Leukemia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>AML</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Elderly</keyword>
	<keyword>Elderly patient eligible intensive chemotherapy</keyword>
</DOC>